PPD opened an office in Istanbul, Turkey as part of the planned growth of its Phase II-IV clinical development services in Eastern Europe. PPD already has offices in Russia and the Ukraine.
PPD will provide clinical monitoring services in key therapeutic areas from this location.
"With a population of 74 million people, Turkey is becoming an attractive place to conduct clinical trials," said Fred Eshelman, CEO of PPD. "Eastern Europe offers recruitment opportunities and quality investigators, and our Istanbul office is an important part of our strategic growth in this region."
Regulations Still Driving Stability Testing
Unlocking the Secrets of Protein Profiling